Latest news and press releases about Perspective Therapeutics, Inc. (CATX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds.
Price
| Price | $2.88 |
| Market Cap | $328M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| Price / Book | 0.59 |
| EV / EBITDA | -2.37 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -41.56% |
| Return on Invested Capital | -34.94% |
| Return on Assets | -29.70% |
| Gross Margin | -419.40% |
| Operating Margin | -34216.39% |
| Net Margin | -31812.57% |
Related companies: AVR · ELMD · HSDT · IVVD · MXCT · NNOX · NYXH
Explore sector: Healthcare · Medical - Devices
More sections of CATX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks